5-((2,6,6-trimethylcyclohex-1-enyl)methoxy)benzo[d][1,3]dioxole | 1441168-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 5-((2,6,6-trimethylcyclohex-1-enyl)methoxy)benzo[d][1,3]dioxole
• 英文别名: 5-((2,6,6-Trimethylcyclohex-1-enyl)methoxy) benzo[d][1,3]dioxole；5-[(2,6,6-trimethylcyclohexen-1-yl)methoxy]-1,3-benzodioxole
• CAS: 1441168-32-6
• 化学式: C₁₇H₂₂O₃
• 分子量: 274.36
• InChiKey: MNFHIDZXCMRVFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-吡咯烷羧酸,3-[[(3-溴苯基)氨基]甲基]-,1,1-二甲基乙基酯 在 sodium cyanoborohydride 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 50.0h， 生成 5-((2,6,6-trimethylcyclohex-1-enyl)methoxy)benzo[d][1,3]dioxole
  参考文献：
  名称：

  [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE
  [FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  揭示了用于治疗由于或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病的化合物和组合物，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂的组合物，以及使用这些化合物和/或组合物的治疗方法。还揭示了合成这些药剂的方法。

  公开号：

  WO2013081642A1

文献信息

• Opsin-Binding Ligands, Compositions and Methods of Use
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：US20150038574A1

  公开（公告）日：2015-02-05

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  本文披露了一些化合物和组合物，用于治疗由于或与眼睛中毒性视觉循环产物积累有关的眼科疾病，如干性成人黄斑变性，以及由突变视蛋白的错误折叠和/或视蛋白的错误定位引起或有关的疾病。描述了这些化合物单独或与其他治疗剂组合的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS)
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3632461A1

  公开（公告）日：2020-04-08

  Disclosed is a group of chimeric antigen receptors (CARs) consisting of two, three or four CAR molecules, wherein the members of the group of CARs can be different or identical in their amino acid sequences to one another, and wherein each of the CAR molecules of the group comprise at least a transmembrane domain and an ectodomain comprising either an antigen binding moiety or a binding site to which another polypeptide is able to bind, wherein the another polypeptide comprises an antigen binding moiety; wherein each CAR molecule of the group comprises at least one dimerization domain, wherein this dimerization of a pair of dimerization domains is either induced by a regulating molecule and optionally reduced by another regulating molecule, or occurs in the absence of a regulating molecule and is reduced by a regulating molecule, and wherein the ectodomain of each CAR molecule of the group in its prevalent conformation is free of cysteine amino acid moieties which are able to form intermolecular disulphide bonds with other CAR molecules of the group, respectively, and wherein the antigen binding moieties of the CAR molecules of the group and of the other polypeptides being able to bind to the CAR molecules of the group are either specific for one target antigen or for a non-covalent or a covalent complex of different target antigens.

  公开了一组嵌合抗原受体（CAR），由两个、三个或四个 CAR 分子组成、 其中，该组 CAR 成员的氨基酸序列可以彼此不同或相同，以及 其中该组的每个 CAR 分子至少包括一个跨膜结构域和一个外结构域，该结构域包括抗原结合分子或另一种多肽可与之结合的结合位点，其中另一种多肽包括抗原结合分子； 其中该组的每个 CAR 分子包括至少一个二聚化结构域，一对二聚化结构域的这种二聚化或者由调节分子诱导并可选地被另一个调节分子降低，或者在没有调节分子的情况下发生并被调节分子降低，以及 其中，该组每个 CAR 分子的外结构域在其盛行构象中不含半胱氨酸氨基酸分子，而半胱氨酸氨基酸分子可分别与该组其他 CAR 分子形成分子间二硫键，以及 其中，该组 CAR 分子和能与该组 CAR 分子结合的其他多肽的抗原结合分子对一种靶抗原或不同靶抗原的非共价或共价复合物具有特异性。
• SWITCH MOLECULE AND SWITCHABLE CHIMERIC ANTIGEN RECEPTOR
  申请人：AbClon Inc.

  公开号：EP3783026A1

  公开（公告）日：2021-02-24

  The present invention relates to a switch molecule for activating a chimeric antigen receptor effector cell, to a polypeptide or fusion protein binding thereto, and to a chimeric antigen receptor. (i) When a switch molecule of the present invention is used, in order to improve safety of a CAR-T cell, if severe toxicity appears, a switch molecule lacking a targeting moiety can be injected to adjust activation of the CAR-T cell. (ii) When an antigen is mutated, or in order to cure various carcinomas, instead of an existing switch molecule, a switch molecule targeting a new antigen generated due to the mutation or a switch molecule targeting a different tumor associated antigen (TAA) can be injected into a patient to cure cancer more effectively.

  本发明涉及一种用于激活嵌合抗原受体效应细胞的开关分子、与之结合的多肽或融合蛋白以及嵌合抗原受体。(i) 当使用本发明的开关分子时，为了提高 CAR-T 细胞的安全性，如果出现严重毒性，可以注射缺乏靶向分子的开关分子来调整 CAR-T 细胞的激活。(ii) 当抗原发生突变时，或为了治愈各种癌症，可以向患者注射靶向因突变而产生的新抗原的开关分子或靶向不同肿瘤相关抗原（TAA）的开关分子，以取代现有的开关分子，从而更有效地治愈癌症。
• C-MET RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF
  申请人：Cedars-Sinai Medical Center

  公开号：EP3791889A1

  公开（公告）日：2021-03-17

  Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.

  本文公开了药物递送分子，该分子包括靶向细胞表面分子的配体、膜穿透结构域和有效载荷结合结构域；以及包含这些分子的药物组合物。还公开了治疗癌症、抑制癌症进展、防止癌症转移以及将治疗化合物递送到需要的受试者脑部的方法，这些方法包括确定需要的受试者；提供包含本文公开的药物递送分子的组合物；以及向受试者施用有效量的组合物。
• Opsin-binding ligands, compositions and methods of use
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：US10040749B2

  公开（公告）日：2018-08-07

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  所公开的化合物和组合物可用于治疗因产生积聚在眼内的有毒视觉循环产物而引起或与之相关的眼科疾病，如干性成人黄斑变性，以及因突变视蛋白的错误折叠和/或视蛋白的错误定位而引起或与之相关的疾病。此外，还描述了这些化合物单独或与其他治疗剂结合的组合物，以及使用这些化合物和/或组合物的治疗方法。还公开了合成此类制剂的方法。